CMS also announced that the penalty phase of its Appropriate Use Criteria Program has been delayed yet again.

A judge from the U.S. International Trade Commission has said Apple violated multiple AliveCor patents. This story, however, is far from over.

The additional costs associated with AFib ablation appear to be justified, researchers wrote.

The initial complaint, filed nearly one year ago, remains unresolved. 

The company will use the funds to follow up on what it learned from the REDUCE LAP-HF II clinical trial.